非小细胞肺癌液体活检的现状与未来展望
Current status and future perspectives of liquid biopsy in non-small cell lung cancer.
作者信息
Chang Sunhee, Hur Jae Young, Choi Yoon-La, Lee Chang Hun, Kim Wan Seop
机构信息
Department of Pathology, Inje University Ilsan Paik Hospital, Goyang, Korea.
Department of Pathology, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea.
出版信息
J Pathol Transl Med. 2020 May;54(3):204-212. doi: 10.4132/jptm.2020.02.27. Epub 2020 Apr 15.
Abstract
With advances in target therapy, molecular analysis of tumors is routinely required for treatment decisions in patients with advanced non-small cell lung cancer (NSCLC). Liquid biopsy refers to the sampling and analysis of circulating cell-free tumor DNA (ctDNA) in various body fluids, primarily blood. Because the technique is minimally invasive, liquid biopsies are the future in cancer management. Epidermal growth factor receptor (EGFR) ctDNA tests have been performed in routine clinical practice in advanced NSCLC patients to guide tyrosine kinase inhibitor treatment. In the near future, liquid biopsy will be a crucial prognostic, predictive, and diagnostic method in NSCLC. Here we present the current status and future perspectives of liquid biopsy in NSCLC.
摘要
随着靶向治疗的进展，对于晚期非小细胞肺癌（NSCLC）患者，肿瘤的分子分析已成为治疗决策的常规要求。液体活检是指对各种体液（主要是血液）中循环游离肿瘤DNA（ctDNA）进行采样和分析。由于该技术具有微创性，液体活检是癌症管理的未来发展方向。表皮生长因子受体（EGFR）ctDNA检测已在晚期NSCLC患者的常规临床实践中开展，以指导酪氨酸激酶抑制剂治疗。在不久的将来，液体活检将成为NSCLC中至关重要的预后、预测和诊断方法。在此，我们介绍NSCLC液体活检的现状和未来展望。
相似文献
1
Current status and future perspectives of liquid biopsy in non-small cell lung cancer.
J Pathol Transl Med. 2020 May;54(3):204-212. doi: 10.4132/jptm.2020.02.27. Epub 2020 Apr 15.
2
Liquid Biopsy in Lung Cancer: Clinical Applications of Circulating Biomarkers (CTCs and ctDNA).
Micromachines (Basel). 2018 Feb 28;9(3):100. doi: 10.3390/mi9030100.
3
[Detection of circulating tumor DNA in epidermal growth factor receptor-TKI relapsed non-small cell lung cancer patients using next-generation sequencing and an analysis of the resistant mechanisms].
Zhonghua Bing Li Xue Za Zhi. 2018 Dec 8;47(12):904-909. doi: 10.3760/cma.j.issn.0529-5807.2018.12.002.
4
Utility of Liquid Biopsy by Improved PNA-LNA PCR Clamp Method for Detecting EGFR Mutation at Initial Diagnosis of Non-Small-Cell Lung Cancer: Observational Study of 190 Consecutive Cases in Clinical Practice.
Clin Lung Cancer. 2018 Mar;19(2):181-190. doi: 10.1016/j.cllc.2017.10.017. Epub 2017 Oct 28.
5
The predictive and prognostic significance of liquid biopsy in advanced epidermal growth factor receptor-mutated non-small cell lung cancer: A prospective study.
Lung Cancer. 2019 Aug;134:187-193. doi: 10.1016/j.lungcan.2019.06.021. Epub 2019 Jun 24.
6
Circulating tumour DNA: A new biomarker to monitor resistance in NSCLC patients treated with EGFR-TKIs.
Biochim Biophys Acta Rev Cancer. 2020 Apr;1873(2):188363. doi: 10.1016/j.bbcan.2020.188363. Epub 2020 Apr 8.
7
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC.
J Thorac Oncol. 2018 Sep;13(9):1248-1268. doi: 10.1016/j.jtho.2018.05.030. Epub 2018 Jun 6.
8
Current and future applications of liquid biopsy in non-small-cell lung cancer-a narrative review.
Transl Lung Cancer Res. 2023 Mar 31;12(3):594-614. doi: 10.21037/tlcr-22-742. Epub 2023 Mar 9.
9
Clinical Utility of Liquid Diagnostic Platforms in Non-Small Cell Lung Cancer.
Oncologist. 2016 Sep;21(9):1121-30. doi: 10.1634/theoncologist.2016-0082. Epub 2016 Jul 7.
10
The Value of Liquid Biopsies for Guiding Therapy Decisions in Non-small Cell Lung Cancer.
Front Oncol. 2019 Mar 5;9:129. doi: 10.3389/fonc.2019.00129. eCollection 2019.
引用本文的文献
1
Lab-in-a-Fiber detection and capture of cells.
Sci Rep. 2025 Mar 20;15(1):9694. doi: 10.1038/s41598-025-92585-6.
2
Comparison of tissue-based and plasma-based testing for EGFR mutation in non-small cell lung cancer patients.
J Pathol Transl Med. 2025 Jan;59(1):60-67. doi: 10.4132/jptm.2024.10.01. Epub 2025 Jan 15.
3
Emerging role of non-invasive and liquid biopsy biomarkers in pancreatic cancer.
World J Gastroenterol. 2023 Apr 21;29(15):2241-2260. doi: 10.3748/wjg.v29.i15.2241.
4
Exosomal MicroRNA Analyses in Esophageal Squamous Cell Carcinoma Cell Lines.
J Clin Med. 2022 Jul 29;11(15):4426. doi: 10.3390/jcm11154426.
5
Alveolar Soft Part Sarcoma of the Uterus: Clinicopathological and Molecular Characteristics.
Diagnostics (Basel). 2022 Apr 27;12(5):1102. doi: 10.3390/diagnostics12051102.
6
Mesonephric-like Adenocarcinoma of the Ovary: Clinicopathological and Molecular Characteristics.
Diagnostics (Basel). 2022 Jan 27;12(2):326. doi: 10.3390/diagnostics12020326.
7
Objective Quantitation of EGFR Protein Levels using Quantitative Dot Blot Method for the Prognosis of Gastric Cancer Patients.
J Gastric Cancer. 2021 Dec;21(4):335-351. doi: 10.5230/jgc.2021.21.e32. Epub 2021 Nov 22.
8
Real-World Analysis of the Mutation Test in Tissue and Plasma Samples from Non-Small Cell Lung Cancer.
Diagnostics (Basel). 2021 Sep 17;11(9):1695. doi: 10.3390/diagnostics11091695.
9
Update on molecular pathology and role of liquid biopsy in nonsmall cell lung cancer.
Eur Respir Rev. 2021 Jul 20;30(161). doi: 10.1183/16000617.0294-2020. Print 2021 Sep 30.
10
Molecular biomarker testing for non-small cell lung cancer: consensus statement of the Korean Cardiopulmonary Pathology Study Group.
J Pathol Transl Med. 2021 May;55(3):181-191. doi: 10.4132/jptm.2021.03.23. Epub 2021 May 11.
本文引用的文献
1
Five Technologies for Detecting the T790M Mutation in the Circulating Cell-Free DNA of Patients With Non-small Cell Lung Cancer: A Comparison.
Front Oncol. 2019 Jul 16;9:631. doi: 10.3389/fonc.2019.00631. eCollection 2019.
2
Next-generation sequencing in liquid biopsy: cancer screening and early detection.
Hum Genomics. 2019 Aug 1;13(1):34. doi: 10.1186/s40246-019-0220-8.
3
PD-L1 Testing in Non-small Cell Lung Cancer: Past, Present, and Future.
J Pathol Transl Med. 2019 Jul;53(4):199-206. doi: 10.4132/jptm.2019.04.24. Epub 2019 May 2.
4
Provisional Guideline Recommendation for EGFR Gene Mutation Testing in Liquid Samples of Lung Cancer Patients: A Proposal by the Korean Cardiopulmonary Pathology Study Group.
J Pathol Transl Med. 2019 May;53(3):153-158. doi: 10.4132/jptm.2019.02.22. Epub 2019 Feb 28.
5
Circulating free tumor DNA in non-small cell lung cancer (NSCLC): clinical application and future perspectives.
J Thorac Dis. 2019 Jan;11(Suppl 1):S113-S126. doi: 10.21037/jtd.2018.12.18.
6
Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time?
Cancer Treat Rev. 2019 Feb;73:73-83. doi: 10.1016/j.ctrv.2019.01.004. Epub 2019 Jan 11.
7
Liquid biopsy using the supernatant of a pleural effusion for EGFR genotyping in pulmonary adenocarcinoma patients: a comparison between cell-free DNA and extracellular vesicle-derived DNA.
BMC Cancer. 2018 Dec 10;18(1):1236. doi: 10.1186/s12885-018-5138-3.
8
Current and future perspectives of liquid biopsies in genomics-driven oncology.
Nat Rev Genet. 2019 Feb;20(2):71-88. doi: 10.1038/s41576-018-0071-5.
9
International pilot external quality assessment scheme for analysis and reporting of circulating tumour DNA.
BMC Cancer. 2018 Aug 9;18(1):804. doi: 10.1186/s12885-018-4694-x.
10
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab.
Nat Med. 2018 Sep;24(9):1441-1448. doi: 10.1038/s41591-018-0134-3. Epub 2018 Aug 6.
Zotero 插件